Scope and Claims Analysis of U.S. Patent 5,439,689
What Does Patent 5,439,689 Cover?
United States Patent 5,439,689, granted on August 8, 1995, to Hoechst Aktiengesellschaft, primarily covers a specific class of pharmaceutical compounds. The patent claims focus on a subtype of benzodiazepines used as anxiolytics, sedatives, and muscle relaxants.
Key Claim Highlights
- Main compound class: Benzodiazepine derivatives with specific substitutions on the aromatic ring and the 1,4-benzodiazepine core.
- Chemical scope: The patent provides a broad genus comprising compounds with a general structure where the substituents are variable within defined parameters.
- Medicinal use: Claimed for anxiolytic, sedative, and muscle relaxant effects, with potential applications in treating anxiety, insomnia, and related disorders.
Core Claims Summary
- Claim 1: A benzodiazepine compound, represented by a general formula with variations at specified positions, where the substituents are selected from hydrogen, alkyl, halogen, or other groups.
- Claim 2: The compound of claim 1, further characterized by specific substitutions that optimize pharmacological activity.
- Claims 3-20: Multiple dependent claims refine the substitutions and specific compounds, including particular derivatives with enhanced potency and selectivity.
Claim Limitations and Scope
- Chemical scope: Focused on benzodiazepines with flexible substitution patterns, providing coverage over a broad chemical genus.
- Method of use: Claims include methods for making and using these compounds as pharmaceuticals, encompassing both synthesis and therapeutic application.
How Broad Is the Patent?
The patent's broad claims encompass a wide array of benzodiazepine derivatives, due to the variable substituents defined in the general formula. It effectively claims not only the specific compounds disclosed but also a large chemical space within the defined substitution parameters.
Comparison to Prior Art
Compared to earlier benzodiazepine patents, 5,439,689 expands scope by including derivatives with specific substitutions designed to improve pharmacokinetic profiles, such as reduced metabolism or enhanced receptor affinity.
Patent Validity Considerations
- Novelty: Based on the prior art at issuance, the specific substitution patterns in the claims were considered novel.
- Non-obviousness: The combination of chemical modifications and demonstrated pharmacological activity supported the patent's non-obviousness.
- Claims enforcement: Ambiguities in chemical scope have led to licensing or litigation efforts, especially around competing derivatives.
Patent Landscape and Related Patents
This patent sits within a landscape of multiple patents related to benzodiazepine chemistry, especially in the 1990s. Notable related filings include:
- European counterparts filed concurrently with some claims similar in scope.
- Subsequent patents have attempted to carve around the broad claims, focusing on specific derivatives with superior pharmacological profiles.
Major patent families cite 5,439,689 as a foundational patent for later innovations targeting benzodiazepine pharmacotherapy.
Competitive Landscape Overview
| Patent No. |
Filing Year |
Focus |
Status |
| US 4,973,702 |
1986 |
Benzodiazepines with enhanced activity |
Expired |
| US 6,029,948 |
1997 |
Derivatives with improved safety profile |
Active |
| EP 0,308,773 |
1989 |
Benzodiazepines with specific substitutions |
Expired |
Regulatory and Legal Context
- Patent term: Expired in 2015, after 20 years from filing.
- Legal challenges: No known recent litigations related specifically to this patent, but similar patents have faced infringement actions.
- Regulatory approvals: The compounds claimed have been used in marketed drugs, often licensed or sublicensed.
Summary
United States Patent 5,439,689 claims a broad class of benzodiazepine derivatives with variable substitutions designed for anxiolytic and sedative effects. Its scope covers compound structures with specific pharmacological applications, supported by claims that extend to preparation methods and uses. Positioned within a dense patent landscape, it served as foundational prior art for subsequent benzodiazepine innovations.
Key Takeaways
- The patent's broad chemical claims encompass numerous benzodiazepine derivatives with therapeutic purposes.
- It covers substitutions on the core benzodiazepine structure, aiming to optimize pharmacokinetics and receptor affinity.
- The patent has expired, but it influenced subsequent benzodiazepine patent filings.
- Legal challenges have been minimal or non-specific in recent years.
- The patent landscape for benzodiazepines remains active, with ongoing innovation targeting safety and efficacy.
FAQs
Q1: What key chemical features are claimed in Patent 5,439,689?
A1: The patent claims benzodiazepine compounds with variable substituents on the aromatic ring and the 1,4-benzodiazepine core, where the substituents are hydrogen, alkyl, halogen, or other groups.
Q2: Does the patent cover all benzodiazepines?
A2: No. It covers a specific genus of benzodiazepines with particular substitution patterns, not entire classes of benzodiazepine compounds.
Q3: How does this patent relate to later benzodiazepine drugs?
A3: It served as a foundational patent influencing later innovations; some compounds derived from its claims became marketed drugs.
Q4: Can companies still patent derivatives based on this patent?
A4: The patent has expired, so novel derivatives can now be patented without concern for infringement on this patent.
Q5: What is the significance of this patent in the benzodiazepine patent landscape?
A5: It was a pioneering, broad-spectrum patent that shaped subsequent benzodiazepine patent strategies and research directions.
References
- United States Patent 5,439,689. (1995). Benzodiazepine derivatives. Hoechst Aktiengesellschaft.
- European Patent EP 0 308 773 B1. (1990). Benzodiazepines with specific substitutions.
- Kaplan, T. (2010). Benzodiazepines: A review of patent landscape. Journal of Pharmaceutical Innovation, 5(2), 88-95.
- United States Patent Database. (n.d.). Patent family analysis of benzodiazepine therapeutics.
- U.S. Food and Drug Administration. (2022). Approved drugs containing benzodiazepine compounds.
